Runben Biotechnology Co Ltd Ordinary Shares - Class A
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd. operates as a subsidiary of Guangzhou Zhuofan Investment Holding Co., L… Read more
Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) - Net Assets
Latest net assets as of September 2025: CN¥2.17 Billion CNY
Based on the latest financial reports, Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) has net assets worth CN¥2.17 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.31 Billion) and total liabilities (CN¥134.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.17 Billion |
| % of Total Assets | 94.19% |
| Annual Growth Rate | 72.17% |
| 5-Year Change | 731.73% |
| 10-Year Change | N/A |
| Growth Volatility | 58.52 |
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Net Assets Trend (2019–2024)
This chart illustrates how Runben Biotechnology Co Ltd Ordinary Shares - Class A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Runben Biotechnology Co Ltd Ordinary Shares - Class A (2019–2024)
The table below shows the annual net assets of Runben Biotechnology Co Ltd Ordinary Shares - Class A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.08 Billion | +8.29% |
| 2023-12-31 | CN¥1.92 Billion | +165.89% |
| 2022-12-31 | CN¥722.59 Million | +28.66% |
| 2021-12-31 | CN¥561.65 Million | +124.53% |
| 2020-12-31 | CN¥250.14 Million | +82.10% |
| 2019-12-31 | CN¥137.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Runben Biotechnology Co Ltd Ordinary Shares - Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 789.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥594.90 Million | 28.59% |
| Common Stock | CN¥404.59 Million | 19.45% |
| Other Components | CN¥1.08 Billion | 51.96% |
| Total Equity | CN¥2.08 Billion | 100.00% |
Runben Biotechnology Co Ltd Ordinary Shares - Class A Competitors by Market Cap
The table below lists competitors of Runben Biotechnology Co Ltd Ordinary Shares - Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Circassia Group Plc
OTCGREY:CSSPF
|
$243.88 Million |
|
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
|
$243.93 Million |
|
Beijing Dataway Horizon Co. Ltd
SHE:301169
|
$243.98 Million |
|
W&T Offshore Inc
NYSE:WTI
|
$243.99 Million |
|
VIKRAM SOLAR LIMITED
NSE:VIKRAMSOLR
|
$243.72 Million |
|
Tristel PLC
PINK:TSNLF
|
$243.69 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
$243.68 Million |
|
Lifestyle Communities Ltd
AU:LIC
|
$243.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Runben Biotechnology Co Ltd Ordinary Shares - Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,921,258,411 to 2,080,453,702, a change of 159,195,291 (8.3%).
- Net income of 300,161,748 contributed positively to equity growth.
- Dividend payments of 136,036,426 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥300.16 Million | +14.43% |
| Dividends Paid | CN¥136.04 Million | -6.54% |
| Other Changes | CN¥-4.93 Million | -0.24% |
| Total Change | CN¥- | 8.29% |
Book Value vs Market Value Analysis
This analysis compares Runben Biotechnology Co Ltd Ordinary Shares - Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 65.92x to 4.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥0.34 | CN¥22.38 | x |
| 2020-12-31 | CN¥0.62 | CN¥22.38 | x |
| 2021-12-31 | CN¥1.39 | CN¥22.38 | x |
| 2022-12-31 | CN¥1.79 | CN¥22.38 | x |
| 2023-12-31 | CN¥5.44 | CN¥22.38 | x |
| 2024-12-31 | CN¥5.13 | CN¥22.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Runben Biotechnology Co Ltd Ordinary Shares - Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.43%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.77%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.07x
- Recent ROE (14.43%) is below the historical average (22.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 25.97% | 12.80% | 1.69x | 1.20x | CN¥21.94 Million |
| 2020 | 37.86% | 21.39% | 1.60x | 1.11x | CN¥69.70 Million |
| 2021 | 21.48% | 20.72% | 0.90x | 1.15x | CN¥64.48 Million |
| 2022 | 22.15% | 18.69% | 1.04x | 1.14x | CN¥87.79 Million |
| 2023 | 11.76% | 21.88% | 0.51x | 1.05x | CN¥33.90 Million |
| 2024 | 14.43% | 22.77% | 0.59x | 1.07x | CN¥92.12 Million |
Industry Comparison
This section compares Runben Biotechnology Co Ltd Ordinary Shares - Class A's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,143,263,014
- Average return on equity (ROE) among peers: 10.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) | CN¥2.17 Billion | 25.97% | 0.06x | $243.86 Million |
| Lonkey Industrial Co Ltd Guangzhou (000523) | $104.40 Million | 15.81% | 1.73x | $549.33 Million |
| Tianjin Yiyi Hygiene Products Co Ltd (001206) | $1.73 Billion | 6.61% | 0.14x | $225.27 Million |
| Hunan Resun Co Ltd (001218) | $905.44 Million | 24.55% | 0.67x | $285.91 Million |
| Dencare (Chongqing) Oral Care Co. Ltd. A (001328) | $542.28 Million | 24.82% | 0.88x | $205.01 Million |
| Qingdao Kingking Applied Chemistry Co Ltd (002094) | $1.92 Billion | 9.63% | 0.50x | $497.23 Million |
| C&S Paper Co Ltd (002511) | $2.28 Billion | 5.08% | 0.97x | $752.42 Million |
| Anhui Deli Household Glass Co Ltd (002571) | $1.41 Billion | -9.08% | 0.25x | $343.86 Million |
| Mingchen Health Co Ltd Class A (002919) | $739.25 Million | 3.43% | 0.68x | $472.78 Million |
| Chongqing Baiya Sanitary Products Co (003006) | $359.21 Million | 16.81% | 0.32x | $497.77 Million |
| Chengdu Rainbow Appliance Gr (003023) | $1.44 Billion | 6.57% | 0.37x | $159.76 Million |